
A panel of expert advisers to the Food and Drug Administration voted unanimously Thursday to recommend that the COVID-19 vaccine be updated to target emerging subvariants of omicron.
The COVID shot that's currently available is known as a "bivalent" vaccine because it was tailored to target both the original strain of the coronavirus and the omicron subvariants that dominated last winter.